Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals shares rose about 1% in premarket trading on Monday after Citizens upgraded the gastrointestinal drugmaker, arguing that pricing pressure on Linzess has eased. Citizens analyst Jason Butler wrote that “LINZESS headwinds have passed” as the stock traded at $4.32 at 6:01 a.m. ET; Wells Fargo also lifted its price target to $5 from $3. The shares closed up 26.7% on Friday at $4.27. Investing